Immunotherapy with ponezumab for probable cerebral amyloid angiopathy

Volume: 6, Issue: 4, Pages: 795 - 806
Published: Mar 18, 2019
Abstract
Cerebral amyloid angiopathy (CAA) is caused by cerebrovascular deposition of β-amyloid fragments leading to cerebrovascular dysfunction and other brain injuries. This phase 2, randomized, double-blind trial in patients with probable CAA assessed the efficacy and safety of ponezumab, a novel monoclonal antibody against Aβ1-40.Thirty-six participants aged 55-80 years with probable CAA received intravenous placebo (n = 12) or ponezumab (n = 24)....
Paper Details
Title
Immunotherapy with ponezumab for probable cerebral amyloid angiopathy
Published Date
Mar 18, 2019
Volume
6
Issue
4
Pages
795 - 806
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.